AR073274A1 - Composicion. uso de un polinucleotido de eif-5a1 truncado para inducir apoptosis en celulas cancerosas - Google Patents

Composicion. uso de un polinucleotido de eif-5a1 truncado para inducir apoptosis en celulas cancerosas

Info

Publication number
AR073274A1
AR073274A1 ARP090103378A ARP090103378A AR073274A1 AR 073274 A1 AR073274 A1 AR 073274A1 AR P090103378 A ARP090103378 A AR P090103378A AR P090103378 A ARP090103378 A AR P090103378A AR 073274 A1 AR073274 A1 AR 073274A1
Authority
AR
Argentina
Prior art keywords
eif5a1
polynucleotide
composition
truncated
host
Prior art date
Application number
ARP090103378A
Other languages
English (en)
Inventor
Zhenyu Cheng
Catherine Taylor
Zhong Sun
Richard S Dondero
John E Thompson
Original Assignee
Senesco Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/400,742 external-priority patent/US8703929B2/en
Application filed by Senesco Technologies Inc filed Critical Senesco Technologies Inc
Publication of AR073274A1 publication Critical patent/AR073274A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Uso combinado de un ARNsi dirigido contra un gen endogeno para bloquear o silenciar la expresion del gen endogeno en un huésped y al suministro de un polinucleotido que codifica el gen en un vehículo de suministro/vector de expresion al huésped para proporcionar expresion en éste de la proteína codificada por el polinucleotido. Se refiere también a una forma truncada de eIF-5A1 que es util para inducir apoptosis y muerte celular, especialmente en células cancerosas en un mamífero Reivindicacion 1: Una composicion que comprende un polinucleotido eIF5A1 que codifica una proteína eIF5A1 truncada. Reivindicacion 5: La composicion de acuerdo con la reivindicacion 1 caracterizada porque el polinucleotido eIF5A1 está comprendido dentro de un plásmido o vector de expresion. Reivindicacion 16: Un polipéptido eIF5A1 truncado aislado formado por la escision mediada por caspasa de eIF5A1. Reivindicacion 17: Una composicion que comprende un polinucleotido eIF5A1 que codifica una proteína eIF5A1 truncada y un polinucleotido eIF5A1 de longitud completa. Reivindicacion 21: La composicion de acuerdo con la reivindicacion 19 caracterizada porque el polinucleotido eIF5As de longitud completa codifica un eIF5A1 mutante en el cual la mutacion previene o inhibe la hipusinacion por desoxihipusina sintasa y/o en el cual la mutacion está presente en el sitio de ubiquinizacion y/o en el sitio de acetilacion. Reivindicacion 23: La composicion de acuerdo con la reivindicacion 21 que comprende además un ARNsi dirigido contra el 3'UTR de eIF5A. Reivindicacion 30: Un método para inducir apoptosis en una célula cancerosa de mamífero o un tumor de mamífero proporcionando al mamífero las composiciones de la reivindicacion 1. Reivindicacion 32: El método de acuerdo con la reivindicacion 30 caracterizado porque el cáncer es mieloma multiple.
ARP090103378A 2008-09-03 2009-09-02 Composicion. uso de un polinucleotido de eif-5a1 truncado para inducir apoptosis en celulas cancerosas AR073274A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9374908P 2008-09-03 2008-09-03
US12/400,742 US8703929B2 (en) 2008-03-07 2009-03-09 Compositions comprising siRNA and plasmids

Publications (1)

Publication Number Publication Date
AR073274A1 true AR073274A1 (es) 2010-10-28

Family

ID=41797839

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090103378A AR073274A1 (es) 2008-09-03 2009-09-02 Composicion. uso de un polinucleotido de eif-5a1 truncado para inducir apoptosis en celulas cancerosas

Country Status (8)

Country Link
EP (1) EP2331142A4 (es)
JP (1) JP2012501650A (es)
CN (1) CN102202693A (es)
AR (1) AR073274A1 (es)
AU (1) AU2009288092A1 (es)
CA (1) CA2735823A1 (es)
TW (1) TW201023898A (es)
WO (1) WO2010028093A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012165672A (ja) * 2011-02-10 2012-09-06 Tottori Univ １塩基認識能を増幅する人工核酸コンジュゲート
JP2015500808A (ja) * 2011-11-30 2015-01-08 セネスコ テクノロジーズ，インコーポレイティド Ｂ細胞リンパ腫の治療
US20150126581A1 (en) * 2012-03-08 2015-05-07 The University Of Western Australia MicroRNAs and Uses Thereof
CN103709238B (zh) * 2013-12-18 2015-04-22 北京市农林科学院 杨树耐盐基因PtoeIF5A1的应用
CN107110848B (zh) 2014-11-07 2020-04-07 藤仓化成株式会社 以脱氧羟腐胺缩赖氨酸合酶基因作为指标使用的动脉硬化及癌的检测方法
WO2016178233A1 (en) * 2015-05-05 2016-11-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Nucleic acid-cationic polymer compositions and methods of making and using the same
CN114231551B (zh) * 2021-12-24 2023-09-29 云南大学 蛋白在促进昆虫淋巴细胞凋亡和/或防治害虫中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ556236A (en) * 2004-12-03 2009-12-24 Senesco Technologies Inc Apoptosis-specific eIF-5A and polynucleotides encoding same
JP2009519351A (ja) * 2005-12-13 2009-05-14 セネスコ テクノロジーズ，インコーポレイティド 多発性骨髄腫細胞を死滅させるためのｅＩＦ−５Ａの使用

Also Published As

Publication number Publication date
EP2331142A4 (en) 2012-08-29
CA2735823A1 (en) 2010-03-11
JP2012501650A (ja) 2012-01-26
TW201023898A (en) 2010-07-01
CN102202693A (zh) 2011-09-28
WO2010028093A3 (en) 2010-08-05
AU2009288092A1 (en) 2010-03-11
WO2010028093A2 (en) 2010-03-11
EP2331142A2 (en) 2011-06-15

Similar Documents

Publication Publication Date Title
AR073274A1 (es) Composicion. uso de un polinucleotido de eif-5a1 truncado para inducir apoptosis en celulas cancerosas
NZ587809A (en) Use of mesenchymal stem cells expressing cd73 and/or cd105 for treating genetic diseases and disorders
Parsons et al. USP47 is a deubiquitylating enzyme that regulates base excision repair by controlling steady-state levels of DNA polymerase β
CL2018001198A1 (es) Métodos y composiciones para edición génica en hemocitoblastos
PE20130213A1 (es) Marcadores predictivos utiles en el tratamiento del sindrome fragil x (fxs)
PE20181206A1 (es) Construcciones especificas del higado, casetes de expresion del factor viii y metodos de uso de estos
PE20121429A1 (es) Nuevo uso antitumoral de cabazitaxel
MX346923B (es) Genes y proteinas para sintesis de alcanoil-coa.
CL2009000082A1 (es) Acido nucleico que codifica anticuerpos anti cd79a o anti cd79b para el tratamiento de tumores hematopoyeticos; vector y células huésped que los comprenden; polipeptido codificado por dicho acido nucleico, inmunoconjugado con el cuerpo.
Liu et al. Zebrafish dead end possesses ATPase activity that is required for primordial germ cell development
AR065075A1 (es) Vectores para la expresion multiple de genes
BR112015011244A8 (pt) análogos de compstatina de reação celular, ação longa ou direcionados e composições e métodos relacionados
BR112013010855A2 (pt) luciferases derivadas de oplophorus, novos substratos de coelenterazina e métodos de uso
MY173998A (en) Glucosylceramide synthase inhibitors
WO2008034866A3 (en) Dbait and uses thereof
CL2011002039A1 (es) Anticuerpo humanizado que se une al cd19 humano; acido nucleico aislado que codifica dicho anticuerpo; vector y celula huesped; composicion e inmunoconjugado; metodo para inhibir el crecimiento de celulas de tumor que expresan cd19.
Tsai et al. RIG1 inhibits the Ras/mitogen-activated protein kinase pathway by suppressing the activation of Ras
PE20091378A1 (es) Polipeptidos agonistas plexind1
ES2383716T3 (es) Composiciones y métodos que utilizan ARN de interferencia de un gen del tipo OPR3 para el control de nemátodos
AR078848A1 (es) Tecnologia terapeutica de arn de interferencia dirigido al oncogen pdx -1 en tumores neuroendocrinos donde se expresa pdx-1
BR112014031526A2 (pt) promotores para expressar um gene em uma célula
Lee et al. Decreased mitochondrial OGG1 expression is linked to mitochondrial defects and delayed hepatoma cell growth
BR112014010053A8 (pt) variantes de isopreno sintase com solubilidade aprimorada para produção de isopreno
Chen et al. C-terminal amino acids 290–328 of LPTS/PinX1 confer telomerase inhibition
ES2351916B8 (es) Metodo de identificacion de celulas madre mesenquimales senescentes

Legal Events

Date Code Title Description
FA Abandonment or withdrawal